Harrow, Inc. (HROW)
30.94
-0.27
(-0.87%)
USD |
NASDAQ |
May 18, 16:00
31.04
+0.10
(+0.32%)
After-Hours: 19:40
Harrow Research and Development Expense (Quarterly) : 5.895M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly & Co. | 3.51B |
| Esperion Therapeutics, Inc. | 8.988M |
| Theravance Biopharma, Inc. | 5.448M |
| Xeris Biopharma Holdings, Inc. | 8.783M |
| Aquestive Therapeutics, Inc. | 4.204M |